rhEPO has been commercially available since 1989 after gaining authorization approval by the FDA (EPOGENR) for use as a valuable biologic medicinal product in the replacement protein therapy (RPT) of chronic renal failure (CRF), that is characterized by insufficient production of EPO. The gene discussed is EPO; the disease is chronic kidney disease.